SCHEMBL30113078

SCHEMBL30113078

O=[N+]([O-])c1cccnc1Nc1cc(F)c(F)c(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.58
NPC1 O15118 6/20 0.50
RAB9A P51151 6/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
NFKB1 P19838 1/20 0.50
MAPK1 P28482 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
GRM4 Q14833 1/20 0.49
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
PKM P14618 3/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
THRB P10828 1/20 0.44
IDO1 P14902 1/20 0.44
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29153613 1.00 MAPT (0.58) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL15954728 0.89 MAPT (0.55) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL2503337 0.87 MAPT (0.59) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL15954532 0.84 MAPT (0.56) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL2779294 0.84 NPC1 (0.58) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL31227406 0.82 MAPT (0.56) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL29241859 0.82 MAPT (0.68) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL6799629 0.82 MAPT (0.56) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL15954408 0.81 MAPT (0.53) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL28784232 0.81 MAPT (0.56) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240276867-A1 DINUCLEAR PLATINUM EMITTER COMPLEXES AND METHODS OF MAKING AND USING THEREOF University of Hong Kong Versitech Limited (CN) 2024-08-15 US disclosed
EP-4347609-A1 DINUCLEAR PLATINUM EMITTER COMPLEXES AND METHODS OF MAKING AND USING THEREOF Versitech Limited (HK) 2024-04-10 EP disclosed
CN-117500814-A Binuclear platinum emitter complex and preparation and use methods thereof 港大科桥有限公司 2024-02-02 CN disclosed
WO-2022253220-A1 DINUCLEAR PLATINUM EMITTER COMPLEXES AND METHODS OF MAKING AND USING THEREOF VERSITECH LIMITED (CN) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240276867-A1 DINUCLEAR PLATINUM EMITTER COMPLEXES AND METHODS OF MAKING AND USING THEREOF OCIAD2, OCIAD1, PDCD2L MAPT 650/4885NPC1 2175/4885RAB9A 2790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.